Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators

Endocrine Reviews

Volumn 25, Issue 1, 2004, Pages 45-71

  Smith, Carolyn L ^a,b   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Dept of Molec and Cellular Biology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AL 438; ANTIGESTAGEN; ANTILIPEMIC AGENT; ASOPRISNIL; DEXAMETHASONE OXETANONE; FULVESTRANT; GESTAGEN; GLUCOCORTICOID ANTAGONIST; ICI 164 384; J 1042; KB 141; LGD 2226; MIFEPRISTONE; N 9 FLUORENYLMETHYLOXYCARBONYLLEUCINE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; ONAPRISTONE; PEPTIDE; PREDNISONE; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; PROMEGESTONE; RECEPTOR BLOCKING AGENT; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATOR; SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR; TAMOXIFEN; THYROID HORMONE; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 137 316; ZK 98 229;

ACNE; AZOOSPERMIA; BLEEDING; BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; GYNECOMASTIA; HEART VENTRICLE HYPERTROPHY; HIRSUTISM; HORMONE ACTION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; KNOCKOUT MOUSE; LIGAND BINDING; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MOOD DISORDER; NONHUMAN; OSTEOPOROSIS; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SEBORRHEA; SIGNAL TRANSDUCTION; TACHYCARDIA; TARGET CELL; TESTIS ATROPHY; TISSUE SPECIFICITY; TREATMENT INDICATION; UROGENITAL TRACT DISEASE; VIRILIZATION;

ANIMALS; FEEDBACK, BIOCHEMICAL; HUMANS; LIGANDS; ORGAN SPECIFICITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 1442351143     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2003-0023     Document Type: Review

References (337)

1. Tsai M-J, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
2. Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
4. Jordan VC, Robinson SP 1987 Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 46:1870-1874
5. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815
6. Gottardis MM, Jordan VC 1987 Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024
7. Jordan VC, Phelps E, Lindergren JU 1987 Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35
8. Harper MJ, Walpole AL 1966 Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212:87
9. Jordan VC 1992 The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70:977-982
10. Williamson JG, Ellis JD 1973 The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw 80:844-847
11. Harper MJ, Walpole AL 1967 A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13:101-119
12. Cole MP, Jones CT, Todd ID 1971 A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25:270-275
13. Early Breast Cancer Trialist Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451-1467
14. Turner RT, Wakley GK, Hannon KS, Bell NH 1987 Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 2:449-456
15. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
16. Moon LY, Wakley GK, Turner RT 1991 Dose-dependent effects of tamoxifen on long bones in growing rats: influence of ovarian status. Endocrinology 129:1568-1574
17. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647
18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637-645
19. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134
20. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD 2000 Lasofoxifene (CP-336, 156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 141:1338-1344
21. Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB 2001 Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61: 8412-8415
22. Miller CP, Harris HA, Komm BS 2002 Bazedoxifene acetate: selective estrogen receptor modulator, treatment and prevention of osteoporosis. Drugs Future 27:117-121
23. 9-dehydroestrone sulfate in postmenopausal women. J Clin Endocrinol Metab 84:2020-2027
24. Kloosterboer HJ 2001 Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 76:231-238
25. Chetrite G, Kloosterboer HJ, Pasqualini JR 1997 Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 17:135-140
26. Chetrite GS, Pasqualini JR 2001 The selective estrogen enzyme modulator (SEEM) in breast cancer. J Steroid Biochem Mol Biol 76:95-104
27. Kloosterboer HJ, Ederveen AGH 2002 Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments. J Steroid Biochem Mol Biol 83:157-165
28. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW 2002 Reproductive functions of progesterone receptors. Recent Prog Horm Res 57:339-355
29. Giannoukos G, Szapary D, Smith CL, Meeker JEW, Simons Jr SS 2001 New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties. Mol Endocrinol 15:255-270
30. Chwalisz K, Garg R, Brenner RM, Schubert G, Elger W 2002 Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann NY Acad Sci 955:373-388
31. Classen-Linke I, Alfer J, Krusche CA, Chwalisz K, Rath W, Beier HM 2000 Progestins, progesterone receptor modulators, and progesterone antagonists change VEGF release of endometrial cells in culture. Steroids 65:763-771
32. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W 2000 Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 65:741-751
33. Chwalisz K, Lamar PR, Williamson S, Larsen L, McCrary K, Elger W, Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867. J Soc Gynecol Invest, in press
34. Mooradian AD, Morley JE, Korenman SG 1987 Biological actions of androgens. Endocr Rev 8:1-28
35. Negro-Vilar A 1999 Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 84:3459-3462
36. Davis S 1999 Androgen replacement in women: a commentary. J Clin Endocrinol Metab 84:1886-1891
37. Zhi L, Tegley CM, Marschke KB, Jones TK 1999 Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g] quinolinone. Bioorg Med Chem Lett 9:1009-1012
38. Edwards JP, West SJ, Pooley CLF, Marschke KB, Farmer LJ, Jones TK 1998 New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H) -pyrrolidino[3,2-g]quinolinone. Bioorg Med Chem Lett 8:745-750
39. Risek B, Miner JN, Evans G, Turner RT, Bain S, Shen V, Chang W, Barnett RW, Schrader WT, Rosen J, Negro-Vilar A, A non-steroidal, selective androgen receptor modulator (SARM) with efficacy on bone in the orchiectomized adult rat. Program of the 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001, p 255 (Abstract P1-497)
40. Schoonjans K, Auwerx J 2000 Thiazolidinediones: an update. Lancet 355:1008-1010
41. Kersten S, Desvergne B, Wahli W 2000 Roles of PPARs in health and disease. Nature 405:421-424
42. Desvergne B, Wahli W 1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688
43. Sporn MB, Suh N, Mangelsdorf DJ 2001 Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs). Trends Mol Med 7:395-400
44. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy M-F, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud J-P, Auwerx J 2001 A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-747
45. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W 2002 A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628-2644
46. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE 2003 Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol Endocrinol 17:662-676
47. Sorbera LA, Rabasseda X 1998 Rosiglitazone maleate. Drugs Future 23:977-985
48. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin C-W, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN 2003 A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 17:860-869
49. Yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142
50. 3 regulation of cholesterol metabolism in mice. Mol Endocrinol 16:1676-1777
51. Yoshihara HAI, Apriletti JW, Baxter JD, Scanlan TS 2003 Structural determinants of selective thyromimetics. J Med Chem 46: 3152-3161
52. Grover GJ, Mellström K, Ye L, Malm J, Li Y-L, Bladh L-G, Sleph PG, Smith MA, George R, Vennström B, Mookhtiar K, Horvath R, Speelman J, Egan D, Baxter JD 2003 Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 100:10067-10072
53. Jensen EV, Jacobson HI 1962 Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18:387-414
54. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930
55. Parker MG 1993 Steroid and related receptors. Cell Biol 5:499-504
56. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson J-A, Carlquist M 1999 Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 18: 4608-4618
57. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang C-Y, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ. Proc Natl Acad Sci USA 96:3999-4004
58. Van den Bemd G-JCM, Kuiper GGJM, Pols HAP, Van Leeuwen JPTM 1999 Distinct effects on the conformation of estrogen receptor α and β by both the antiestrogens ICI 164, 384 and ICI 182, 780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun 261:1-5
59. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S 1997 Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J Biol Chem 272:25832-25838
60. Cowley SM, Hoare S, Mosselman S, Parker MG 1997 Estrogen receptors α and β form heterodimers on DNA. J Biol Chem 272: 19858-19862
61. Hall JM, McDonnell DP 1999 The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566-5578
62. Delaunay F, Pettersson K, Tujague M, Gustafsson J-Å 2000 Functional differences between the amino-terminal domains of estrogen receptors α and β. Mol Pharmacol 58:584-590
63. Métivier R, Stark A, Flouriot G, Hübner MR, Brand H, Penot G, Manu D, Denger S, Reid G, Kos M, Russell RB, Kah O, Pakdel F, Gannon F 2002 A dynamic structural model for estrogen receptor-α activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell 10:1019-1032
64. Beekman JM, Allan GF, Tsai SY, Tsai M-J, O'Malley BW 1993 Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7:1266-1274
65. Fritsch M, Leary CM, Furlow JD, Ahrens H, Schuh TJ, Mueller GC, Gorski J 1992 A ligand-induced conformational change in the estrogen receptor is localized in the steroid binding domain. Biochemistry 31:5303-5311
66. McKenna NJ, Lanz RB, O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344
67. Robyr D, Wolffe AP, Wahli W 2000 Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 14:329-347
68. Hermanson O, Glass CK, Rosenfeld MG 2002 Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 13:55-60
69. McKenna NJ, O'Malley BW 2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-474
70. Jordan VC 1984 Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245-276
71. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson J 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870
72. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson J-Å 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263.
73. Berry M, Metzger D, Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2812
74. Webster NJG, Green S, Jin J-R, Chambon P 1988 The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54:199-207
75. Tora L, White JH, Brou C, Tasset DM, Webster NJG, Scheer E, Chambon P 1989 The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487
76. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30
77. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
78. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M 1997 Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors α and β. Biochem Biophys Res Commun 236:140-145
79. Jones PS, Parrott E, White IN 1999 Activation of transcription by estrogen receptor α and β is cell type-and promoter-dependent. J Biol Chem 274:32008-32014
80. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P 2000 Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317
81. Safe S 2001 Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62:231-252
82. Martin PM, Berthois Y, Jensen EV 1988 Binding of anti-estrogens exposes an occult antigenic determinant in the human estrogen receptor. Proc Natl Acad Sci USA 85:2533-2537
83. Allan GF, Leng XH, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW 1992 Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-19520
84. Kuil CW, Berrevoets CA, Mulder E 1995 Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 270:27569-27576
85. Modarress KJ, Opoku J, Xu M, Sarlis NJ, Simons Jr SS 1997 Steroid-induced conformational changes at ends of the hormone-binding domain in the rat glucocorticoid receptor are independent of agonist versus antagonist activity. J Biol Chem 272:23986-23994
86. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD 1996 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195
87. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
88. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J-Å, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
89. Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li Y-L, Gustafsson J-Å, Carlquist M 2001 Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-153
90. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG 1990 Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883-6887
91. Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA 2002 Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Mol Endocrinol 16:2706-2719
92. Dauvois S, Danielian S, White R, Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041
93. Htun H, Holth LT, Walker D, Davie JR, Hager GL 1999 Direct visualization of the human estrogen receptor α reveals a role for ligand in the nuclear distribution of the receptor. Mol Biol Cell 10:471-486
94. Dauvois S, White R, Parker MG 1993 The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388
95. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini M 2001 FRAP reveals that mobility of oestrogen receptor-a is ligand- and proteasome-dependent. Nat Cell Biol 3:15-23
96. Stenoien DL, Mancini MG, Patel K, Allegretto EA, Smith CL, Mancini MA 2000 Subnuclear trafficking of estrogen receptor-α and steroid receptor coactivator-1. Mol Endocrinol 14:518-534
97. McDonnell DP, Chang C-Y, Norris JD 2000 Development of peptide antagonists that target estrogen receptor-cofactor interactions. J Steroid Biochem Mol Biol 74:327-335
98. Chang C-Y, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP 1999 Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β. Mol Cell Biol 19:8226-8239
99. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP 1999 Peptide antagonists of the human estrogen receptor. Science 285:744-746
100. Chang C-Y, McDonnell DP 2002 Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 16:647-660
101. Baniahmad A, Leng X, Burris TP, Tsai SY, Tsai M-J, O'Malley BW 1995 The τ4 activation domain of the thyroid hormone receptor is required to release a corepressor(s) necessary for transcriptional silencing. Mol Cell Biol 15:76-86
102. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW 1992 The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713
103. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M 1994 Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455-1458
104. Onate SA, Tsai SY, Tsai M-J, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357
105. Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667-3675
106. Hong H, Kohli K, Garabedian MJ, Stallcup MR 1997 GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17:2735-2744
107. Li H, Gomes PJ, Chen JD 1997 RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94:8479-8484
108. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580
109. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S-C, Heyman RA, Rose DW, Glass CK, Rosenfeld MG 1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414
110. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-684
111. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968
112. Takeshita A, Yen PM, Misiti S, Cardona GR, Liu Y, Chin WW 1996 Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology 137:3594-3597
113. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736
114. McInerney EM, Rose DW, Flynn SE, Westin S, Mullen T-M, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, Milburn MV, Glass CK, Rosenfeld MG 1998 Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 12:3357-3368
115. Mak HY, Hoare S, Henttu PMA, Parker MG 1999 Molecular determinants of the estrogen receptor-coactivator interface. Mol Cell Biol 19:3895-3903
116. Danielian PS, White R, Lees JA, Parker MG 1992 Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025-1033
117. Henttu PM, Kalkhoven E, Parker MG 1997 AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol Cell Biol 17:1832-1839
118. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang S-M, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 12:1605-1618
119. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen T-M, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920-2925
120. Kobayashi Y, Kitamoto T, Masuhiro Y, Watanabe M, Kase T, Metzger D, Yanagisawa J, Kato S 2000 p300 Mediates functional synergism between AF-1 and AF-2 of estrogen receptor α and β by interacting directly with the N-terminal A/B domains. J Biol Chem 275:15645-15651
121. Gill G, Ptashne M 1988 Negative effect of the transcriptional activator GAL4. Nature 334:721-724
122. Meyer ME, Gronemeyer H, Turcotte B, Bocquel M-T, Tasset D, Chambon P 1989 Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57:433-442
123. Cavailles V, Dauvois S, Danielian PS, Parker MG 1994 Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91:10009-10013
124. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai M-J, O'Malley BW 1999 A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97:17-27
125. Chen D, Huang S-M, Stallcup MR 2000 Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem 275:40810-40816
126. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR 1999 Regulation of transcription by a protein methyltransferase. Science 284:2174-2177
127. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai M-J, O'Malley BW 1999 The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 19:1182-1189
128. Imhof MO, McDonnell DP 1996 Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol Cell Biol 16:2594-2605
129. Auboeuf D, Hönig A, Berget SM, O'Malley BW 2002 Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298:416-419
130. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, Spiegelman BM 2000 Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell 6:307-316
131. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939-948
132. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852
133. Liu Z, Wong J, Tsai SY, Tsai M-J, O'Malley BW 2001 Sequential recruitment of steroid receptor coactivator-1 (SRC-1) and p300 enhances progesterone receptor-dependent initiation and reinitiation of transcription from chromatin. Proc Natl Acad Sci USA 98:12426-12431
134. Burakov D, Crofts LA, Chang C-PB, Freedman LP 2002 Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. J Biol Chem 277:14359-14362
135. McNally JG, Müller WG, Walker D, Wolford R, Hager GL 2000 The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 287:1262-1265
136. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG 1999 Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13:3198-3208
137. Chen D, Umesono K, Evans RM 1996 SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc Natl Acad Sci USA 93:7567-7571
138. Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK 1995 Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377:451-454
139. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamel Y, Soderstrom M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377: 397-404
140. Leng X, Tsai SY, O'Malley BW, Tsai M-J 1993 Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor. J Steroid Biochem Mol Biol 46:643-661
141. Schulman IG, Juguilon H, Evans RM 1996 Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states. Mol Cell Biol 16: 3807-3813
142. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705
143. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
144. Dotzlaw H, Moehren U, Mink S, Cato ACB, Lluhi JAI, Baniahmad A 2002 The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16: 661-673
145. Schulz M, Eggert M, Baniahmad A, Dostert A, Heinzel T, Renkawitz R 2002 RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J Biol Chem 277:26238-26243
146. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
147. Huang H-J, Norris JD, McDonnell DP 2002 Identification of a negative regulatory surface within estrogen receptor α provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol Endocrinol 16:1778-1792
148. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel G, Glass CK, Rose DW, Rosenfeld MG 2000 Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753-763
149. Rajendran RR, Nye AC, Frasor J, Balsara RD, Martini PGV, Katzenellenbogen BS 2003 Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97). J Biol Chem 278:4628-4638
150. Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O, Lee HS, Eng F, Bertos NR, Pelletier N, Mader S, Han VKM, Yang X-J, White JH 2003 Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell 11:139-150
151. Sohn Y-C, Kim S-W, Lee S, Kong Y-Y, Na DS, Lee S-K, Lee JW 2003 Dynamic inhibition of nuclear receptor activation by corepressor binding. Mol Endocrinol 17:366-372
152. Liao G, Chen L-Y, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD 2003 Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 278:5052-5061
153. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP 1998 The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18: 1369-1378
154. Laherty CD, Billin AN, Lavinsky RM, Yochum GS, Bush AC, Sun J-M, Mullen T-M, Davie JR, Rose DW, Glass CK, Rosenfeld MG, Ayer DE, Eisenman RN 1998 SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell 2:33-42
155. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380
156. Heinzel T, Lavinsky RM, Mullen T-M, Torchia J, Yang W-M, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG 1997 A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48
157. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai C-C, Hon M, Evans RM 2001 Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes Dev 15:1140-1151
158. Mazumdar A, Wang R-A, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R 2001 Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30-37
159. Windahl SH, Treuter E, Ford J, Zilliacus J, Gustafsson J-A, McEwan IJ 1999 The nuclear-receptor interacting protein (RIP) 140 binds to the human glucocorticoid receptor and modulates hormone-dependent transactivation. J Steroid Biochem Mol Biol 71: 93-102
160. Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson J-A 1998 A regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol 12:864-881
161. Delage-Mourroux R, Martini PGV, Choi I, Kraichely DM, Hoeksema J, Katzenellenbogen BS 2000 Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J Biol Chem 275:35848-35856
162. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS 1999 An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 96: 6947-6952
163. Norris JD, Fan D, Sherk A, McDonnell DP 2002 A negative coregulator for the human ER. Mol Endocrinol 16:459-468
164. Zhang H, Thomsen JS, Johansson L, Gustafsson J-Å, Treuter E 2000 DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. J Biol Chem 275:39855-39859
165. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, Tsai M-J, O'Malley BW 2002 Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA 99:7940-7944
166. Szapary D, Huang Y, Simons Jr SS 1999 Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol Endocrinol 13:2108-2121
167. He Y, Szapary D, Simons Jr SS 2002 Modulation of induction properties of glucocorticoid receptor-agonist and -antagonist complexes by coactivators involves binding to receptors but is independent of ability of coactivators to augment transactivation. J Biol Chem 277:49256-49266
168. Segars JH, Driggers PH 2002 Estrogen action and cytoplasmic signaling cascades. I. Membrane-associated signaling complexes. Trends Endocrinol Metab 13:349-354
169. Driggers PH, Segars JH 2002 Estrogen action and cytoplasmic signaling pathways. II. The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 13:422-427
170. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson J-Å 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565
171. McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS 1998 Transcription activation by the human estrogen receptor subtype β(ERβ) studied with ERβ and ERα receptor chimeras. Endocrinology 139:4513-4522
172. Cowley SM, Parker MG 1999 A comparison of transcriptional activation by ERα and ERβ. J Steroid Biochem Mol Biol 69:165-175
173. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J-Å, Nilsson S 1998 Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54:105-112
174. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites. Science 277:1508-1510
175. Wärnmark A, Almlöf T, Leers J, Gustafsson J-Å, Treuter E 2001 Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERα and ERβ. J Biol Chem 276: 23397-23404
176. Kressler D, Schreiber SN, Knutti D, Kralli A 2002 The PGC-1-related protein PERC is a selective coactivator of estrogen receptor α. J Biol Chem 277:13918-13925
177. Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, Hashimoto S, Kato S 1999 Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α. Mol Cell Biol 19:5363-5372
178. Watanabe M, Yanagisawa J, Kitagawa H, Takeyama K-I, Ogawa S, Arao Y, Suzawa M, Kobayashi Y, Yano T, Yoshikawa H, Masuhiro Y, Kato S 2001 A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor α coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J 20:1341-1352
179. Wu X, Li H, Chen JD 2001 The human homologue of the yeast DNA repair and TFIIH regulator MMS19 is an AF-1-specific coactivator of estrogen receptor. J Biol Chem 276:23962-23968
180. Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS 2000 Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-α and estrogen receptor-β: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141:3534-3545
181. Wong C-W, Komm B, Cheskis BJ 2001 Structure-Function evaluation of ER α and β interplay with SRC family coactivators. ER selective ligands. Biochemistry 40:6756-6765
182. Cheskis BJ, McKenna NJ, Wong C-W, Wong J, Komm B, Lyttle CR, O'Malley BW 2003 Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members. J Biol Chem 278:13271-13277
183. Bramlett KS, Wu Y, Burris TP 2001 Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol Endocrinol 15:909-922
184. Bramlett KS, Burris TP 2002 Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. Mol Gene Metab 76:225-233
185. Routledge EJ, White R, Parker MG, Sumpter JP 2000 Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) α and ERβ. J Biol Chem 275:35986-35993
186. Yudt MR, Cidlowski JA 2001 Molecular identification and characterization of A and B forms of the glucocorticoid receptor. Mol Endocrinol 15:1093-1103
187. Yudt MR, Cidlowski JA 2002 The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol 16:1719-1726
188. Conneely OM, Maxwell BL, Toft DO, Schrader WT, O'Malley BW 1987 The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem Biophys Res Commun 149:493-501
189. Kastner P, Krust A, Turcotte B, Strupp U, Tora L, Gronemeyer H, Chambon P 1990 Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
190. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP 1993 Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244-1255
191. McDonnell DP, Goldman ME 1994 RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem 269:11945-11949
192. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265
193. Giangrande PH, Pollio G, McDonnell DP 1997 Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J Biol Chem 272:32889-32900
194. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP 2000 The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20:3102-3115
195. Li X, Wong J, Tsai SY, Tsai M-J, O'Malley BW 2003 Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 23:3763-3773
196. Klinge CM 2001 Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905-2919
197. Loven MA, Wood JR, Nardulli AM 2001 Interaction of estrogen receptors α and β with estrogen response elements. Mol Cell Endocrinol 181:151-163
198. Wood JR, Likhite VS, Loven MA, Nardulli AM 2001 Allosteric modulation of estrogen receptor conformation by different estrogen response elements. Mol Endocrinol 15:1114-1126
199. Loven MA, Likhite VS, Choi I, Nardulli AM 2001 Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor β conformation. J Biol Chem 276: 45282-45288
200. Yi P, Driscoll MD, Huang J, Bhagat S, Hill R, Bambara RA, Muyan M 2002 The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ERα and ERβ. Mol Endocrinol 16:674-693
201. Lefstin JA, Yamamoto KR 1998 Allosteric effects of DNA on transcriptional regulators. Nature 392:885-888
202. Ikeda M, Wilcox EC, Chin WW 1996 Different DNA elements can modulate the conformation of thyroid hormone receptor heterodimer and its transcriptional activity. J Biol Chem 271:23096-23104
203. Hall JM, McDonnell DP, Korach KS 2002 Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol 16:469-486
204. Barkhem T, Haldosén L-A, Gustafsson J-Å, Nilsson S 2002 Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-α depends on the coactivator subtype, the type of estrogen response element, and the promoter context. Mol Endocrinol 16:2571-2581
205. Berry M, Nunez A-M, Chambon P 1989 Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86:1218-1222
206. Cavarretta ITR, Mukopadhyay R, Lonard DM, Cowsert LM, Bennett CF, O'Malley BW, Smith CL 2002 Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERα transcriptional activity and MCF-7 proliferation. Mol Endocrinol 16: 253-270
207. Dubik D, Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7:1587-1594
208. Augereau P, Miralles F, Cavailles V, Gaudelet C, Parker M, Rochefort H 1994 Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol 8:693-703
209. Lannigan DA 2003 Estrogen receptor phosphorylation. Steroids 68:1-9
210. Weigel NL 1996 Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319:657-667
211. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ 2002 Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277:29304-29314
212. Coleman KM, Smith CL 2001 Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 6:D1379-D1391
213. Dutertre M, Smith CL 2003 Ligand-independent interactions of p160/SRC coactivators and CBP with estrogen receptor-α: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 17:1296-1314
214. Tremblay A, Tremblay GB, Labrie F, Giguère V 1999 Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell 3:513-519
215. Tremblay A, Giguère V 2001 Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor β. J Steroid Biochem Mol Biol 77:19-27
216. Rowan BG, Weigel NL, O'Malley BW 2000 Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 275:4475-4483
217. Rowan BG, Garrison N, Weigel NL, O'Malley BW 2000 8-Bromocyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 20:8720-8730
218. Ueda T, Mawji NR, Bruchovsky N, Sadar MD 2002 Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094
219. Coleman KM, Dutertre M, El-Gharbawy A, Rowan BG, Weigel NL, Smith CL 2003 Mechanistic differences in the activation of estrogen receptor-α (ERα)- and ERβ-dependent gene expression by cAMP signaling pathway(s). J Biol Chem 278:12834-12845
220. Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ 2001 Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 co-activator activity. J Biol Chem 276:22177-22182
221. Font de Mora JF, Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20:5041-5047
222. Wu R-C, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai M-J, O'Malley BW 2002 Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by IκB kinase. Mol Cell Biol 22:3549-3561
223. Qutob MS, Bhattacharjee RN, Pollari E, Yee SP, Torchia J 2002 Microtubule-dependent subcellular redistribution of the transcriptional coactivator p/CIP. Mol Cell Biol 22:6611-6626
224. Ko L, Cardona GR, Chin WW 2000 Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 97:6212-6217
225. Iwasaki T, Chin WW, Ko L 2001 Identification and characterization of RRM-containing coactivator activator (CoAA) as TRBP-interacting protein, and its splice variant as a coactivator modulator (CoAM). J Biol Chem 276:33375-33383
226. Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson J-Å 2000 Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J Biol Chem 275:5308-5317
227. Lee S-K, Anzick SL, Choi J-E, Bubendorf L, Guan X-Y, Jung Y-K, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun B-H, Cheong JH, Lee YC, Meltzer PS, Lee JW 1999 A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem 274:34283-34293
228. Ko L, Cardona GR, Iwasaki T, Bramlett KS, Burris TP, Chin WW 2002 Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. Mol Endocrinol 16:128-140
229. Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai M-Y, Yeh S, Wu G, Guo Y, Chang C 2002 Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 277:15426-15431
230. Yuan LW, Soh J-W, Weinstein IB 2002 Inhibition of histone acetyltransferase function of p300 by PKCδ. Biochim Biophys Acta 1592: 205-211
231. Yang W, Hong YH, Shen X-Q, Frankowski C, Camp HS, Leff T 2001 Regulation of transcription by AMP-activated protein kinase. Phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem 276:38341-38344
232. See RH, Calvo D, Shi Y, Kawa H, Luke MP-S, Yuan Z, Shi Y 2001 Stimulation of p300-mediated transcription by the kinase MEKK1. J Biol Chem 276:16310-16317
233. MAPK cascade. J Biol Chem 273:32400-32407
234. Janknecht R, Nordheim A 1996 MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. Biochem Biophys Res Commun 228:831-837
235. Hong S-H, Privalsky ML 2000 The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol 20:6612-6625
236. Knutti D, Kressler D, Kralli A 2001 Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci USA 98:9713-9718
237. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, Spiegelman BM 2001 Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1. Mol Cell 8:971-982
238. Ichida M, Nemoto S, Finkel T 2002 Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α). J Biol Chem 277:50991-50995
239. Espinosa L, Inglés-Esteve J, Robert-Moreno A, Bigas A 2003 IκBα and p65 regulate the cytoplasmic shuttling of nuclear corepressors: cross-talk between notch and NFκB pathways. Mol Biol Cell 14: 491-502
240. Zilliacus J, Holter E, Wakui H, Tazawa H, Treuter E, Gustafsson J-Å 2001 Regulation of glucocorticoid receptor activity by 14-3-3-dependent intracellular relocalization of the corepressor RIP140. Mol Endocrinol 15:501-511
241. Wijayaratne AL, McDonnell DP 2001 The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
242. Lange CA, Shen T, Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97:1032-1037
243. Wallace JD, Cidlowski JA 2001 Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 276:42714-42721
244. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM 2000 Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation. J Biol Chem 275:18527-18533
245. Voges D, Zwickl P, Baumeister W 1999 The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68:1015-1068
246. Baumeister W, Walz J, Zühl F, Seemüller E 1998 The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367-380
247. Lonard DM, Smith CL 2002 Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67:15-24
248. Lin H-K, Altuwaijri S, Lin W-J, Kan P-Y, Collins LL, Chang C 2002 Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277:36570-36576
249. Deroo BJ, Rentsch C, Sampath S, Young J, DeFranco DB, Archer TK 2002 Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol Cell Biol 22:4113-4123
250. Deroo BJ, Archer TK 2002 Proteasome inhibitors reduce luciferase and γ-galactosidase activity in tissue culture cells. J Biol Chem 277:20120-20123
251. Wang X, Pongrac JL, DeFranco DB 2002 Glucocorticoid receptors in hippocampal neurons that do not engage proteasomes escape from hormone-dependent down-regulation but maintain transactivation activity. Mol Endocrinol 16:1987-1998
252. Reid G, Hübner MR, Métivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695-707
253. Yan F, Gao X, Lonard DM, Nawaz Z 2003 Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol Endocrinol 17:1315-1331
254. Kang Z, Pirskanen A, Janne OA, Palvimo JJ 2002 Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277:48366-48371
255. Kotaja N, Karvonen U, Jänne OA, Palvimo JJ 2002 PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol 22:5222-5234
256. Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E 2003 Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278:12335-12343
257. Muller S, Hoege C, Pyrowolakis G, Jentsch S 2001 SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2:202-210
258. Melchior F 2000 SUMO-nonclassical ubiquitin. Annu Rev Cell Dev Biol 16:591-626
259. Yeh ETH, Gong L, Kamitani T 2000 Ubiquitin-like proteins: new wines in new bottles. Gene 248:1-14
260. Kotaja N, Karvonen U, Jänne OA, Palvimo JJ 2002 The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277:30283-30288
261. vom Baur E, Zechel C, Heery D, Heine MJS, Garnier JM, Vivat V, Le Douarin B, Gronemeyer H, Chambon P, Losson R 1996 Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J 15:110-124
262. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM 1999 BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284:1354-1356
263. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM 2001 Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20:77-87
264. Fan S, Ma YX, Wang C, Yuan R-Q, Meng Q, Wang J-A, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM 2002 p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 62:141-151
265. Zhang J, Guenther MG, Carthew RW, Lazar MA 1998 Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes Dev 12:1775-1780
266. Ordentlich P, Downes M, Xie W, Genin A, Spinner NB 1999 Unique forms of human and mouse nuclear receptor corepressor SMRT. Proc Natl Acad Sci USA 96:2639-2644
267. Della NG, Senior PV, Bowtell DD 1993 Isolation and characterisation of murine homologues of the Drosophila seven in absentia gene (sina). Development 117:1333-1343
268. Koh SS, Chen D, Lee YH, Stallcup MR 2001 Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem 276:1089-1098
269. Ma H, Baumann CT, Li H, Strahl BD, Rice R, Jelinek MA, Aswad DW, Allis CD, Hager GL, Stallcup MR 2001 Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Curr Biol 11:1981-1985
270. Bauer U-M, Daujat S, Nielsen SJ, Nightingale K, Kouzarides T 2001 Methylation at arginine 17 of histone H3 is linked to gene activation. EMBO Rep 31:39-44
271. Xu W, Chen H, Du K, Asahara H, Tini M, Emerson BM, Montminy M, Evans RM 2001 A transcriptional switch mediated by cofactor methylation. Science 294:2507-2511
272. Lee Y-H, Koh SS, Zhang X, Cheng X, Stallcup MR 2002 Synergy among nuclear receptor coactivators: selective requirement for protein methyltransferase and acetyltransferase activities. Mol Cell Biol 22:3621-3632
273. Chevillard-Briet M, Trouche D, Vandel L 2002 Control of CBP co-activating activity by arginine methylation. EMBO J 21:5457-5466
274. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM 1999 Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-686
275. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SAW, Lopez GN, Kushner PJ, Pestell RG 2001 Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 6:18375-18383
276. Loven MA, Muster N, Yates JR, Nardulli AM 2003 A novel estrogen receptor α-associated protein, template-activating factor 1β, inhibits acetylation and transactivation. Mol Endocrinol 17:67-78
277. Kadener S, Cramer P, Nogues G, Cazalla D, de la Mata M, Fededa JP, Werbajh SE, Srebrow A, Kornblihtt AR 2001 Antagonistic effects of T-Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing. EMBO J 20:5759-5768
278. Hönig A, Auboeuf D, Parker MM, O'Malley BW, Berget SM 2002 Regulation of alternative splicing by the ATP-dependent DEAD-box RNA helicase p72. Mol Cell Biol 22:5698-5707
279. Liu Z-R 2002 p68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5′ splice site duplex. Mol Cell Biol 22:5443-5450
280. Puigserver P, Adelmant G, Wu Z, Fan M, Xu J, O'Malley BW, Spiegelman BM 1999 Activation of PPARγ coactivator-1 through transcription factor docking. Science 286:1368-1371
281. Slagsvold T, Kraus I, Fronsdal K, Saatcioglu F 2001 DNA binding-independent transcriptional activation by the androgen receptor through triggering of coactivators. J Biol Chem 276:31030-31036
282. Ko L, Cardona GR, Henrion-Caude A, Chin WW 2002 Identification and characterization of a tissue-specific coactivator, GT198, that interacts with the DNA-binding domains of nuclear receptors. Mol Cell Biol 22:357-369
283. Knutti D, Kaul A, Kralli A 2000 A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol 20:2411-2422
284. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schule R 2000 FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 19:359-369
285. Misiti S, Schomburg L, Yen PM, Chin WW 1998 Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology 139:2493-2500
286. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM 1994 Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 8:869-884
287. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW 2000 The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 97:6379-6384
288. Li H, Chen JD 1998 The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation. J Biol Chem 273:5948-5954
289. Apostolakis EM, Ramamurphy M, Zhou D, Onate S, O'Malley BW 2002 Acute disruption of select steroid receptor coactivators prevents reproductive behavior in rats and unmasks genetic adaptation in knockout mice. Mol Endocrinol 16:1511-1523
290. Gregory CW, Wilson EM, Apparao KBC, Lininger RA, Meyer WR, Kowalik A, Fritz MA, Lessey BA 2002 Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab 87:2960-2966
291. Nephew KP, Ray S, Hlaing M, Ahluwalia A, Wu SD, Long X, Hyder SM, Bigsby RM 2000 Expression of estrogen receptor coactivators in the rat uterus. Biol Reprod 63:361-367
292. Shiozawa T, Shih H-C, Miyamoto T, Feng Y-Z, Uchikawa J, Itoh K, Konishi I 2003 Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. J Clin Endocrinol Metab 88:871-878
293. Lauritsen KJ, List H-J, Reiter R, Wellstein A, Riegel AT 2002 A role for TGF-β in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 21:7147-7155
294. Thenot S, Charpin M, Bonnet S, Cavailles V 1999 Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 156:85-93
295. Akiyama N, Matsuo Y, Sai H, Noda M, Kizaka-Kondoh S 2000 Identification of a series of transforming growth factor β-responsive genes by retrovirus-mediated gene trap screening. Mol Cell Biol 20:3266-3273
296. Borud B, Hoang T, Bakke M, Jacob AL, Lund J, Mellgren G 2002 The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1. Mol Endocrinol 16:757-773
297. Li Q, Su A, Chen J, Lefebvre YA, Haché RJG 2002 Attenuation of glucocorticoid signaling through targeted degradation of p300 via the 26S proteasome pathway. Mol Endocrinol 16:2819-2827
298. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P, Theillet C 1998 In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4:2925-2929
299. Murphy LC, Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, Troup S, Adeyinka A, Watson PH 2000 Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 60:6266-6271
300. Leygue E, Dotzlaw H, Watson PH, Murphy LC 1999 Expression of the steroid receptor RNA activator in human breast tumors. Cancer Res 59:4190-4193
301. Bouras T, Southey MC, Venter DJ 2001 Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu1. Cancer Res 61:903-907
302. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361
303. Girault I, Lerebours R, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I 2003 Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9:1259-1266
304. Balen A 2001 Polycystic ovary syndrome and cancer. Hum Reprod Update 7:522-555
305. Kumar R, Wang R-A, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK 2002 A naturally occurring MTA1 variant sequesters oestrogen receptor-γ in the cytoplasm. Nature 418:654-657
306. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H 2000 Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin Cancer Res 6:512-518
307. Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH 2002 Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 87:1411-1416
308. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319
309. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, O'Malley BW 1998 Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922-1925
310. Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P 2002 The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol 22:5923-5937
311. Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG 2000 Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci USA 97:13549-13554
312. Antonson P, Schuster GU, Wang L, Rozell B, Holter E, Flodby P, Treuter E, Holmgren L, Gustafsson J-A 2003 Inactivation of the nuclear receptor coactivator RAP250 in mice results in placental vascular dysfunction. Mol Cell Biol 23:1260-1268.
313. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, Sweatt JD, Beaudet AL 1998 Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21:799-811
314. White R, Leonardsson G, Rosewell I, Jacobs MA, Milligan S, Parker M 2000 The nuclear receptor co-repressor Nrip1 (RIP140) is essential for female fertility. Nat Med 6:1368-1374
315. Smith CL, DeVera DG, Lamb DJ, Nawaz Z, Jiang Y-H, Beaudet AL, O'Malley BW 2002 Genetic ablation of the steroid receptor coactivator-ubiquitin ligase, E6-AP, results in tissue-selective steroid hormone resistance and defects in reproduction. Mol Cell Biol 22:525-535
316. Picard F, Géhin M, Annicotte J-S, Rocchi S, Champy M-F, O'Malley BW, Chambon P, Auwerx J 2002 SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111:931-941
317. Weiss RE, Xu J, Ning G, Pohlenz J, O'Malley BW, Refetoff S 1999 Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 18:1900-1904
318. 3-regulated transcription of genes in vivo. Endocrinology 143:1346-1352
319. Sadow PM, Chassande O, Gauthier K, Samarut J, Xu J, O'Malley BW, Weiss RE 2003 Specificity of thyroid hormone receptor subtype and steroid receptor coactivator-1 on thyroid hormone action. Am J Physiol 284:E36-E46
320. Weiss RE, Gehin M, Xu J, Sadow PM, O'Malley BW, Chambon P, Refetoff S 2002 Thyroid function in mice with compound heterozygous and homozygous disruptions of SRC-1 and TIF-2 coactivators: evidence for haploinsufficiency. Endocrinology 143:1554-1557
321. Tanaka Y, Naruse I, Maekawa T, Masuya H, Shiroishi T, Ishii S 1997 Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome. Proc Natl Acad Sci USA 94:10215-10220
322. Tanaka Y, Naruse I, Hongo T, Xu M, Nakahata T, Maekawa T, Ishii S 2000 Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. Mech Dev 95:133-145
323. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R 1998 Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361-372
324. Ito M, Yuan C-X, Okano HJ, Darnell RB, Roeder RG 2000 Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. Mol Cell 5:683-693
325. Goodman RH, Smolik S 2000 CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-1577
326. Ito M, Roeder RG 2001 The TRAP/SMCC/mediator complex and thyroid hormone receptor function. Trends Endocrinol Metab 12:127-134
327. Kung AL, Rebel VI, Bronson RT, Ch'ng L-E, Sieff CA, Livingston DM, Yao T-P 2000 Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14:272-277
328. Lyttle CR, Novel SERMs for hormone therapy. Proc 50th Annual Meeting of the Society for Gyneacological Investigation, Washington, DC, 2003, p 8 (Abstract)
329. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG 2000 p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853-20860
330. Pazin MJ, Kadonaga JT 1997 What's up and down with histone deacetylation and transcription? Cell 89:325-328
331. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly J-M, Ali S 2000 Activation of estrogen receptor α by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 6:127-137
332. Bastien J, Adam-Stitah S, Riedl T, Egly J-M, Chambon P, Rochette-Egly C 2000 TFIIH interacts with the retinoic acid receptor γ and phosphorylates its AF-1-activating domain through cdk7. J Biol Chem 275:21896-21904
333. Fan M, Bigsby RM, Nephew KP 2003 The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERγ-positive breast cancer cells. Mol Endocrinol 17:356-365
334. Fan M, Long X, Bailey JA, Reed CA, Osborne E, Gize EA, Kirk EA, Bigsby RM, Nephew KP 2002 The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 16:315-330
335. Ma Z-Q, Liu Z, Ngan ESW, Tsai SY 2001 Cdc25B functions as a novel coactivator for the steroid receptors. Mol Cell Biol 21:8056-8067
336. Poukka H, Karvonen U, Janne OA, Palvimo JJ 2003 Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad of Sci USA 97:14145-14150
337. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM 2003 Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300:342-344